PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Medulloblastoma (MB) is a highly aggressive pediatric brain tumor with limited treatment options.
• Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a known oncogenic protein implicated in various cancers.
• The specific role of PELP1 in medulloblastoma progression has not been previously established.

Purpose of the Study:

• To investigate the role of PELP1 in the progression of pediatric medulloblastoma.
• To determine if PELP1 could serve as a potential therapeutic target for MB.

Main Methods:

• Immunohistochemical analysis of MB tissue microarrays to assess PELP1 expression.
• In vitro studies involving PELP1 knockdown in MB cell lines to evaluate effects on proliferation, survival, and invasion.
• RNA-sequencing and gene set enrichment analysis to identify PELP1-regulated pathways.
• In vivo orthotopic mouse models to assess the impact of PELP1 knockdown on tumor progression and survival.

Main Results:

• PELP1 was found to be overexpressed in medulloblastoma tissues compared to normal brain.
• PELP1 knockdown significantly inhibited MB cell proliferation, survival, and invasion.
• PELP1 knockdown downregulated pathways associated with inflammation, extracellular matrix remodeling, and angiogenesis.
• PELP1 knockdown reduced NF-κB signaling, including target gene expression and p65 nuclear translocation.
• In vivo, PELP1 knockdown suppressed MB tumor growth and improved overall survival in mice.

Conclusions:

• PELP1 plays a critical role in medulloblastoma progression by promoting proliferation, survival, invasion, and associated signaling pathways.
• PELP1 inhibition demonstrates significant anti-tumor effects in both in vitro and in vivo medulloblastoma models.
• PELP1 represents a promising novel therapeutic target for the treatment of pediatric medulloblastoma.